N. Lahlou and M. Roger, Physiologie de la sécrétion de l'hormone de croissance, Médecine Thérapeutique Endocrinol, vol.4, issue.1, pp.4-14, 2002.

, WHO Multicentre Growth Reference Study Group. WHO Child Growth Standards based on length/height, weight and age, Acta Paediatr. Oslo Nor, vol.450, pp.76-85, 1992.

M. De-onis, A. W. Onyango, E. Borghi, A. Siyam, C. Nishida et al., Development of a WHO growth reference for school-aged children and adolescents, Bull. World Health Organ, vol.85, issue.9, pp.660-667, 2007.

M. Sempé, G. Pédron, and R. Mp, Croissance totale ou l'impératif de la taille, Auxol. Méthodes Séquences Paris Théraplix, pp.25-36, 1979.

P. Scherdel, L. Dunkel, P. Van-dommelen, O. Goulet, J. Salaün et al., Growth monitoring as an early detection tool: a systematic review, Lancet Diabetes Endocrinol, vol.4, issue.5, pp.447-456, 2016.

R. M. Blizzard, History of growth hormone therapy, Indian J. Pediatr, vol.79, issue.1, pp.87-91, 2012.

M. L. Davenport, Growth hormone therapy in Turner syndrome, Pediatr. Endocrinol. Rev. PER, vol.9, issue.2, pp.723-724, 2012.

J. I. Labarta, J. A. Ruiz, I. Molina, D. Arriba, A. Mayayo et al., Growth and growth hormone treatment in short stature children born small for gestational age, Pediatr. Endocrinol. Rev. PER, vol.6, issue.3, pp.350-357, 2009.

C. L. Deal, M. Tony, C. Höybye, D. B. Allen, M. Tauber et al., Growth Hormone in Prader-Willi Syndrome Clinical Care Guidelines Workshop Participants. GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome, J. Clin. Endocrinol. Metab, vol.98, issue.6, pp.1072-1087, 2011.

A. Cicognani, P. Pirazzoli, A. Nicoletti, F. Baronio, V. Conti et al., The SHOX gene: a new indication for GH treatment, J. Endocrinol. Invest, vol.33, issue.6, pp.15-18, 2010.

B. S. Finkelstein, T. F. Imperiale, T. Speroff, U. Marrero, D. J. Radcliffe et al., Effect of growth hormone therapy on height in children with idiopathic short stature: a meta-analysis, Arch. Pediatr. Adolesc. Med, vol.156, issue.3, pp.230-240, 2002.

J. Bryant, L. Baxter, C. B. Cave, and R. Milne, Recombinant growth hormone for idiopathic short stature in children and adolescents, Cochrane Database Syst. Rev, issue.3, p.4440, 2007.

J. Carel, J. Tresca, M. Letrait, J. Chaussain, Y. Lebouc et al., Growth Hormone Testing for the Diagnosis of Growth Hormone Deficiency in Childhood: A Population RegisterBased Study, J. Clin. Endocrinol. Metab, vol.82, issue.7, pp.2117-2121, 1997.

M. Tauber, P. Moulin, C. Pienkowski, B. Jouret, and P. Rochiccioli, Growth hormone (GH) retesting and auxological data in 131 GH-deficient patients after completion of treatment, J. Clin. Endocrinol. Metab, vol.82, issue.2, pp.352-356, 1997.

M. Maghnie, C. Strigazzi, C. Tinelli, M. Autelli, M. Cisternino et al., Growth Hormone (GH) Deficiency (GHD) of Childhood Onset: Reassessment of GH Status and Evaluation of the Predictive Criteria for Permanent GHD in Young Adults, J. Clin. Endocrinol. Metab, vol.84, issue.4, pp.1324-1328, 1999.

G. Marin, H. M. Domené, K. M. Barnes, B. J. Blackwell, F. G. Cassorla et al., The effects of estrogen priming and puberty on the growth hormone response to standardized treadmill exercise and arginine-insulin in normal girls and boys, J. Clin. Endocrinol. Metab, vol.79, issue.2, pp.537-541, 1994.

A. L. Rosenbloom, Sex Hormone Priming for Growth Hormone Stimulation Testing in Pre-and Early Adolescent Children Is Evidence Based, Horm. Res. Paediatr, vol.75, issue.1, pp.78-80, 2011.

A. S. Martínez, H. M. Domené, M. G. Ropelato, H. G. Jasper, P. A. Pennisi et al., Estrogen priming effect on growth hormone (GH) provocative test: a useful tool for the diagnosis of GH deficiency, J. Clin. Endocrinol. Metab, vol.85, issue.11, pp.4168-4172, 2000.

L. Lazar and M. Phillip, Is Sex Hormone Priming in Peripubertal Children prior to Growth Hormone Stimulation Tests Still Appropriate?, Horm. Res. Paediatr, vol.73, issue.4, pp.299-302, 2010.

M. Bullinger, M. Ko?towska-häggström, D. Sandberg, J. Chaplin, H. Wollmann et al., Health-related quality of life of children and adolescents with growth hormone deficiency or idiopathic short stature -part 2: available results and future directions, Horm. Res, vol.72, issue.2, pp.74-81, 2009.

J. M. Wit, G. A. Kamp, and B. Rikken, Spontaneous growth and response to growth hormone treatment in children with growth hormone deficiency and idiopathic short stature, Pediatr. Res, vol.39, issue.2, pp.295-302, 1996.

C. Bensignor, J. De-monléon, M. Polak, J. Carel, and F. Huet, Taille finale des déficits somatotropes traités précocement : un modèle thérapeutique, Arch. Pédiatrie, vol.16, issue.6, pp.548-550, 2009.
DOI : 10.1016/s0929-693x(09)74062-x

, GH chez l'enfant non déficitaire, document long, HAS, 2011.

J. Carel, E. Ecosse, M. Nicolino, M. Tauber, J. Leger et al., Adult height after long term treatment with recombinant growth hormone for idiopathic isolated growth hormone deficiency: observational follow up study of the French population based registry, BMJ, vol.325, issue.7355, p.70, 2002.

A. Deodati and S. Cianfarani, Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review, BMJ, vol.342, p.7157, 2011.

D. K. Stephure, Canadian Growth Hormone Advisory Committee. Impact of growth hormone supplementation on adult height in turner syndrome: results of the Canadian randomized controlled trial, J. Clin. Endocrinol. Metab, vol.90, issue.6, pp.3360-3366, 2005.

S. Watanabe, S. Mizuno, L. H. Oshima, Y. Tsunematsu, J. Fujimoto et al., Leukemia and other malignancies among GH users, J. Pediatr. Endocrinol, vol.6, issue.1, pp.99-108, 1993.
DOI : 10.1515/jpem.1993.6.1.99

, Critical Evaluation of the Safety of Recombinant Human Growth Hormone Administration: Statement from the Growth Hormone Research Society, J. Clin. Endocrinol. Metab, vol.86, issue.5, pp.1868-1870, 2001.

S. Malozowski, L. A. Tanner, D. K. Wysowski, G. A. Fleming, and B. V. Stadel, Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone, J. Pediatr, vol.126, issue.6, pp.996-999, 1995.
DOI : 10.1016/s0022-3476(95)70232-6

W. S. Cutfield, P. Wilton, H. Bennmarker, K. Albertsson-wikland, P. Chatelain et al., Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment, The Lancet, vol.355, issue.9204, pp.610-613, 2000.

P. J. Jenkins, A. Mukherjee, and S. M. Shalet, Does growth hormone cause cancer?, Clin. Endocrinol. (Oxf.), vol.64, issue.2, pp.115-121, 2006.
DOI : 10.1111/j.1365-2265.2005.02404.x
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2265.2005.02404.x

J. Bell, K. L. Parker, R. D. Swinford, A. R. Hoffman, T. Maneatis et al., Long-term safety of recombinant human growth hormone in children, J. Clin. Endocrinol. Metab, vol.95, issue.1, pp.167-177, 2010.

B. Ergun-longmire, A. C. Mertens, P. Mitby, J. Qin, G. Heller et al., Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor, J. Clin. Endocrinol. Metab, vol.91, issue.9, pp.3494-3498, 2006.

A. J. Swerdlow, R. Cooke, K. Albertsson-wikland, B. Borgström, G. Butler et al., Description of the SAGhE Cohort: A Large European Study of Mortality and Cancer Incidence Risks after Childhood Treatment with Recombinant Growth Hormone, Horm. Res. Paediatrics, vol.84, issue.3, pp.172-183, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01811057

J. Carel, E. Ecosse, F. Landier, D. Meguellati-hakkas, F. Kaguelidou et al., Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study, J. Clin. Endocrinol. Metab, vol.97, issue.2, pp.416-425, 2012.

L. Sävendahl, M. Maes, K. Albertsson-wikland, B. Borgström, J. Carel et al., Long-Term Mortality and Causes of Death in Isolated GHD, ISS, and SGA Patients Treated with Recombinant Growth Hormone during Childhood in Belgium, The Netherlands, and Sweden: Preliminary Report of 3 Countries Participating in the EU SAGhE Study, J. Clin. Endocrinol. Metab, vol.97, issue.2, pp.213-217, 2012.

D. B. Allen, Growth Hormone Post-Marketing Surveillance: Safety, Sales, and the Unfinished Task Ahead, J. Clin. Endocrinol. Metab, vol.95, issue.1, pp.52-55, 2010.

Y. Chhabra, M. J. Waters, and A. J. Brooks, Role of the growth hormone-IGF-1 axis in cancer, Expert Rev. Endocrinol. Metab, vol.6, issue.1, pp.71-84, 2011.

D. Rizzoni, E. Porteri, A. Giustina, C. De-ciuceis, I. Sleiman et al., Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries, Hypertension, vol.43, issue.3, pp.561-565, 2004.

G. Brevetti, P. Marzullo, A. Silvestro, R. Pivonello, G. Oliva et al., Early Vascular Alterations in Acromegaly, J. Clin. Endocrinol. Metab, vol.87, issue.7, pp.3174-3179, 2002.

R. Manara, P. Maffei, V. Citton, S. Rizzati, G. Bommarito et al., Increased Rate of Intracranial Saccular Aneurysms in Acromegaly: An MR Angiography Study and Review of the Literature, J. Clin. Endocrinol. Metab, vol.96, issue.5, pp.1292-1300, 2011.

P. Delafontaine, Y. Song, and Y. Li, Expression, Regulation, and Function of IGF-1, IGF-1R, and IGF-1 Binding Proteins in Blood Vessels, Arterioscler. Thromb. Vasc. Biol, vol.24, issue.3, pp.435-444, 2004.

G. Li, J. Rincon, . Del, L. A. Jahn, Y. Wu et al., Growth Hormone Exerts Acute Vascular Effects Independent of Systemic or Muscle Insulin-like Growth Factor I, J. Clin. Endocrinol. Metab, vol.93, issue.4, pp.1379-1385, 2008.

R. Usher and F. Mclean, Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation, J. Pediatr, vol.74, issue.6, pp.901-910, 1969.

G. Moulis, M. Lapeyre-mestre, A. Palmaro, G. Pugnet, J. Montastruc et al., French health insurance databases: What interest for medical research? Rev, Médecine Interne, vol.36, issue.6, pp.411-417, 2015.

P. Tuppin, L. De-roquefeuil, A. Weill, P. Ricordeau, and Y. Merlière, French national health insurance information system and the permanent beneficiaries sample, Rev. DÉpidémiologie Santé Publique, vol.58, issue.4, pp.286-290, 2010.

C. Sudlow and C. P. Warlow, Comparable Studies of the Incidence of Stroke and its Pathological Types Results From an International Collaboration, Stroke, vol.28, issue.3, pp.491-499, 1997.

M. Lemesle, C. Milan, J. Faivre, T. Moreau, M. Giroud et al., Incidence Trends of Ischemic Stroke and Transient Ischemic Attacks in a Well-Defined French Population From, Stroke, vol.30, issue.2, pp.371-377, 1985.

P. Rothwell, A. Coull, M. Giles, S. Howard, L. Silver et al., Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from, Oxford Vascular Study). The Lancet, vol.363, issue.9425, pp.1925-1933, 1981.

E. B. Hook and R. R. Regal, Recommendations for presentation and evaluation of capture-recapture estimates in epidemiology, J. Clin. Epidemiol, vol.52, issue.10, pp.917-926, 1999.

E. B. Hook and R. R. Regal, Capture-recapture methods in epidemiology: methods and limitations, Epidemiol. Rev, vol.17, issue.2, pp.243-264, 1995.

M. A. Evans and D. G. Bonett, Bias reduction for multiple-recapture estimators of closed population size, Biometrics, vol.50, issue.2, pp.388-395, 1994.

L. J. Machlin, Effect of porcine growth hormone on growth and carcass composition of the pig, J. Anim. Sci, vol.35, issue.4, pp.794-800, 1972.

V. G. Smith, A. D. Leman, W. J. Seaman, and F. Vanravenswaay, Pig weaning weight and changes in hematology and blood chemistry of sows injected with recombinant porcine somatotropin during lactation, J. Anim. Sci, vol.69, issue.9, pp.3501-3510, 1991.

J. Jakubowski and B. Kendall, Coincidental aneurysms with tumours of pituitary origin, J. Neurol. Neurosurg. Psychiatry, vol.41, issue.11, pp.972-979, 1978.

S. Wakai, T. Fukushima, T. Furihata, and K. Sano, Association of cerebral aneurysm with pituitary adenoma, Surg. Neurol, vol.12, issue.6, pp.503-507, 1979.

M. Acqui, L. Ferrante, B. Fraioli, F. Cosentino, A. Fortuna et al., Association between intracranial aneurysms and pituitary adenomas. AEtiopathogenetic hypotheses, Neurochirurgia (Stuttg.), vol.30, issue.6, pp.177-181, 1987.
DOI : 10.1055/s-2008-1054091

B. Weir, Pituitary tumors and aneurysms: case report and review of the literature, Neurosurgery, vol.30, issue.4, pp.585-591, 1992.

Y. Shimizu, H. Imano, T. Ohira, A. Kitamura, M. Kiyama et al., Adult Height and Body Mass Index in Relation to Risk of Total Stroke and its Subtypes: The Circulatory Risk in Communities Study, J. Stroke Cerebrovasc. Dis. Off. J. Natl. Stroke Assoc, 2013.

, Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis, Int. J. Epidemiol, vol.41, issue.5, pp.1419-1433, 2012.

K. Honjo, H. Iso, M. Inoue, and S. Tsugane, Adult height and the risk of cardiovascular disease among middle aged men and women in Japan, Eur. J. Epidemiol, vol.26, issue.1, pp.13-21, 2011.

Y. Song, G. D. Smith, and J. Sung, Adult height and cause-specific mortality: a large prospective study of South Korean men, Am. J. Epidemiol, vol.158, issue.5, pp.479-485, 2003.

C. Lee, F. Barzi, M. Woodward, G. D. Batty, G. G. Giles et al., Adult height and the risks of cardiovascular disease and major causes of death in the Asia-Pacific region: 21,000 deaths in 510,000 men and women, Int. J. Epidemiol, vol.38, issue.4, pp.1060-1071, 2009.

F. Brancati, M. Castori, R. Mingarelli, and B. Dallapiccola, Majewski osteodysplastic primordial dwarfism type II (MOPD II) complicated by stroke: clinical report and review of cerebral vascular anomalies, Am. J. Med. Genet. A, vol.139, issue.3, pp.212-215, 2005.

S. Miskinyte, M. G. Butler, D. Hervé, C. Sarret, M. Nicolino et al., TournierLasserve E. Loss of BRCC3 deubiquitinating enzyme leads to abnormal angiogenesis and is associated with syndromic moyamoya, Am. J. Hum. Genet, vol.88, issue.6, pp.718-728, 2011.

D. J. Barker, P. D. Gluckman, K. M. Godfrey, J. E. Harding, J. A. Owens et al., Fetal nutrition and cardiovascular disease in adult life, Lancet, vol.341, issue.8850, pp.938-941, 1993.

N. Møller and J. Jørgensen, Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects, Endocr. Rev, vol.30, issue.2, pp.152-177, 2009.

A. Vijayakumar, R. Novosyadlyy, Y. Wu, S. Yakar, and D. Leroith, Biological effects of growth hormone on carbohydrate and lipid metabolism, Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc, vol.20, issue.1, pp.1-7, 2010.

M. A. Sperling, Traditional and novel aspects of the metabolic actions of growth hormone, Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc, 2015.

B. Nellemann, M. H. Vendelbo, T. S. Nielsen, A. M. Bak, M. Høgild et al., Growth hormone-induced insulin resistance in human subjects involves reduced pyruvate dehydrogenase activity, Acta Physiol. Oxf. Engl, vol.210, issue.2, pp.392-402, 2014.

A. Colao, D. Ferone, P. Marzullo, and G. Lombardi, Systemic complications of acromegaly: epidemiology, pathogenesis, and management, Endocr. Rev, vol.25, issue.1, pp.102-152, 2004.

S. Fieffe, I. Morange, P. Petrossians, P. Chanson, V. Rohmer et al., Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry, Eur. J. Endocrinol. Eur. Fed. Endocr. Soc, vol.164, issue.6, pp.877-884, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00811962

D. B. Allen, P. Backeljauw, M. Bidlingmaier, B. Biller, M. Boguszewski et al., GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults, Eur. J. Endocrinol, vol.174, issue.2, pp.1-9, 2016.

M. Van-dijk, E. Bannink, Y. K. Van-pareren, P. Mulder, and A. Hokken-koelega, Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (sga) and untreated short SGA controls, J. Clin. Endocrinol. Metab, vol.92, issue.1, pp.160-165, 2007.

K. Stochholm and G. Johannsson, Reviewing the safety of GH replacement therapy in adults

, Growth Horm. IGF Res. Off. J. Growth Horm. Res. Soc. Int. IGF Res. Soc, vol.25, issue.4, pp.149-157, 2015.

A. Poidvin, E. Touze, E. Ecosse, F. Landier, Y. Bejot et al., Growth hormone treatment for childhood short stature and risk of stroke in early adulthood, Neurology, vol.83, issue.9, pp.780-786, 2014.

C. Giannini, A. Mohn, and F. Chiarelli, Growth abnormalities in children with type 1 diabetes, juvenile chronic arthritis, and asthma, Int. J. Endocrinol, p.265954, 2014.

W. Bonfig, T. Kapellen, A. Dost, M. Fritsch, T. Rohrer et al., Diabetes Patienten Verlaufsdokumentationssystem Initiative of the German Working Group for Pediatric Diabetology and the German Bundesministerium für Bildung und Forschung Competence Net for Diabetes Mellitus. Growth in children and adolescents with type 1 diabetes, J. Pediatr, vol.160, issue.6, pp.900-903, 2012.

C. Lévy-marchal and P. Czernichow, Small for gestational age and the metabolic syndrome: which mechanism is suggested by epidemiological and clinical studies?, Horm. Res, vol.65, pp.123-130, 2006.

P. Saenger, P. Czernichow, I. Hughes, and E. O. Reiter, Small for gestational age: short stature and beyond, Endocr. Rev, vol.28, issue.2, pp.219-251, 2007.

P. H. Whincup, S. J. Kaye, C. G. Owen, R. Huxley, D. G. Cook et al., Birth weight and risk of type 2 diabetes: a systematic review, JAMA, vol.300, issue.24, pp.2886-2897, 2008.

T. Harder, E. Rodekamp, K. Schellong, J. W. Dudenhausen, and A. Plagemann, Birth Weight and Subsequent Risk of Type 2 Diabetes: A Meta-Analysis, Am. J. Epidemiol, vol.165, issue.8, pp.849-857, 2007.

Y. Li, S. H. Ley, D. K. Tobias, S. E. Chiuve, T. J. Vanderweele et al., Birth weight and later life adherence to unhealthy lifestyles in predicting type 2 diabetes: prospective cohort study, BMJ, vol.351, p.3672, 2015.

P. Ricci, P. Blotière, and A. Weill, Diabète traité : quelles évolutions entre 2000 et 2009 en France ?, 2010.

T. Meas, S. Deghmoun, C. Alberti, E. Carreira, P. Armoogum et al., Independent effects of weight gain and fetal programming on metabolic complications in adults born small for gestational age, Diabetologia, vol.53, issue.5, pp.907-913, 2010.

J. Dal, E. O. List, J. Jørgensen, and D. E. Berryman, Glucose and Fat Metabolism in Acromegaly: From Mice Models to Patient Care, Neuroendocrinology, vol.103, issue.1, pp.96-105, 2016.

C. L. Ronchi, V. Varca, P. Beck-peccoz, E. Orsi, F. Donadio et al., Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors, J. Clin. Endocrinol. Metab, vol.91, issue.1, pp.121-128, 2006.

R. H. Willemsen, S. P. Willemsen, and A. Hokken-koelega, Longitudinal changes in insulin sensitivity and body composition of small-for-gestational-age adolescents after cessation of growth hormone treatment, J. Clin. Endocrinol. Metab, vol.93, issue.9, pp.3449-3454, 2008.

S. De-kort, R. H. Willemsen, D. Van-der-kaay, and H. Acs, The effect of growth hormone treatment on metabolic and cardiovascular risk factors is similar in preterm and term short, small for gestational age children, Clin. Endocrinol. (Oxf.), vol.71, issue.1, pp.65-73, 2009.

C. Bonaldi, M. Vernay, C. Roudier, B. Salanave, A. Oleko et al., A first national prevalence estimate of diagnosed and undiagnosed diabetes in France in 18-to 74-year-old individuals: the French Nutrition and Health Survey, Diabet. Med, vol.28, issue.5, pp.583-589, 2006.

. Mandereau-bruno, Prevalence of people pharmacologically treated for diabetes and territorial variations in France in 2012, BEH, pp.30-31, 2014.

P. Noize, F. Bazin, C. Dufouil, N. Lechevallier-michel, M. Ancelin et al., Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study, Pharmacoepidemiol. Drug Saf, vol.18, issue.4, pp.310-319, 2009.

A. A. Samani, S. Yakar, D. Leroith, and P. Brodt, The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights, Endocr. Rev, vol.28, issue.1, pp.20-47, 2007.

E. Seccareccia and P. Brodt, The role of the insulin-like growth factor-I receptor in malignancy: An update, Growth Horm. IGF Res, vol.22, issue.6, pp.193-199, 2012.

A. G. Renehan, M. Zwahlen, C. Minder, O. Dwyer, S. T. Shalet et al., Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis, The Lancet, vol.363, issue.9418, pp.1346-1353, 2004.
DOI : 10.1016/s0140-6736(04)16044-3

M. N. Pollak, E. S. Schernhammer, and S. E. Hankinson, Insulin-like growth factors and neoplasia, Nat. Rev. Cancer, vol.4, issue.7, pp.505-518, 2004.
DOI : 10.1002/0470869976.ch6

J. K. Perry, B. S. Emerald, H. C. Mertani, and P. E. Lobie, The oncogenic potential of growth hormone, Growth Horm. IGF Res, vol.16, issue.5-6, pp.277-289, 2006.
URL : https://hal.archives-ouvertes.fr/hal-00118988

J. K. Perry, D. Liu, Z. Wu, T. Zhu, and P. E. Lobie, Growth hormone and cancer: an update on progress, Curr. Opin. Endocrinol. Diabetes Obes, vol.20, issue.4, pp.307-313, 2013.

R. W. Lea, T. Dawson, C. G. Martinez-moreno, N. El-abry, and S. Harvey, Growth hormone and cancer: GH production and action in glioma?, Gen. Comp. Endocrinol, vol.220, pp.119-123, 2015.

J. Guevara-aguirre, P. Balasubramanian, M. Guevara-aguirre, M. Wei, F. Madia et al., Growth Hormone Receptor Deficiency is Associated With a Major Reduction in Pro-aging Signaling, Cancer and Diabetes in Humans, Sci. Transl. Med, vol.3, issue.70, pp.70-83, 2011.

O. Shevah and Z. Laron, Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: A preliminary report, Growth Horm. IGF Res, vol.17, issue.1, pp.54-57, 2007.

J. Green, B. J. Cairns, D. Casabonne, F. L. Wright, G. Reeves et al., Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk, Lancet Oncol, vol.12, issue.8, pp.785-794, 2011.

J. Sung, Y. Song, D. A. Lawlor, G. D. Smith, and S. Ebrahim, Height and site-specific cancer risk: A cohort study of a korean adult population, Am. J. Epidemiol, vol.170, issue.1, pp.53-64, 2009.

D. Gunnell, M. May, Y. Ben-shlomo, J. Yarnell, and G. D. Smith, Height, leg length, and cancer: the Caerphilly Study, Nutr. Cancer, vol.47, issue.1, pp.34-39, 2003.
DOI : 10.1207/s15327914nc4701_4

G. D. Batty, F. Barzi, M. Woodward, K. Jamrozik, J. Woo et al., Adult height and cancer mortality in Asia: the Asia Pacific Cohort Studies Collaboration, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO, vol.21, issue.3, pp.646-654, 2010.
DOI : 10.1093/annonc/mdp363
URL : https://academic.oup.com/annonc/article-pdf/21/3/646/398026/mdp363.pdf

G. D. Batty, M. J. Shipley, C. Langenberg, M. G. Marmot, and G. D. Smith, Adult height in relation to mortality from 14 cancer sites in men in London (UK): evidence from the original Whitehall study, Ann. Oncol, vol.17, issue.1, pp.157-166, 2006.

*. Collaboration and . Terf, Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis, Int. J. Epidemiol, p.86, 2012.

G. C. Kabat, M. Heo, V. Kamensky, A. B. Miller, and T. E. Rohan, Adult height in relation to risk of cancer in a cohort of Canadian women, Int. J. Cancer, vol.132, issue.5, pp.1125-1132, 2013.

R. B. Walter, T. M. Brasky, S. A. Buckley, J. D. Potter, and E. White, Height as an Explanatory Factor for Sex Differences in Human Cancer, J. Natl. Cancer Inst, vol.105, issue.12, pp.860-868, 2013.

, Leukaemia in patients treated with growth hormone, Lancet Lond. Engl, vol.1, issue.8595, pp.1159-1160, 1988.

A. J. Swerdlow, C. D. Higgins, P. Adlard, and M. A. Preece, Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study, Lancet Lond. Engl, vol.360, issue.9329, pp.273-277, 2002.

C. A. Sklar, A. C. Mertens, P. Mitby, G. Occhiogrosso, J. Qin et al., Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study, J. Clin. Endocrinol. Metab, vol.87, issue.7, pp.3136-3141, 2002.

, InVS > Cancers > Surveillance épidémiologique des cancers en France > Principaux acteurs et partenaires institutionnels, 2015.

P. Kaatsch, J. Strothotte, C. Becker, S. Bielack, U. Dirksen et al., Pediatric bone tumors in Germany from 1987 to 2011: incidence rates, time trends and survival, Acta Oncol. Stockh. Swed, vol.55, issue.9, pp.1145-1151, 2016.

G. Gatta, R. Capocaccia, D. Angelis, R. Stiller, C. Coebergh et al., Cancer survival in European adolescents and young adults, Eur. J. Cancer Oxf. Engl, vol.39, issue.18, pp.2600-2610, 1990.

M. C. Slootweg, S. C. Van-buul-offers, M. P. Herrmann-erlee, J. M. Van-der-meer, and S. A. Duursma, Growth hormone is mitogenic for fetal mouse osteoblasts but not for undifferentiated bone cells, J. Endocrinol, vol.116, issue.3, pp.11-13, 1988.
DOI : 10.1677/joe.0.116r011

A. Lindahl, A. Nilsson, and O. G. Isaksson, Effects of growth hormone and insulin-like growth factor-I on colony formation of rabbit epiphyseal chondrocytes at different stages of maturation, J. Endocrinol, vol.115, issue.2, pp.263-271, 1987.

A. Giustina, G. Mazziotti, and E. Canalis, Growth Hormone, Insulin-Like Growth Factors, and the Skeleton, Endocr. Rev, vol.29, issue.5, pp.535-559, 2008.
DOI : 10.1210/er.2007-0036
URL : https://academic.oup.com/edrv/article-pdf/29/5/535/10334503/edrv0535.pdf

K. H. Gelberg, E. F. Fitzgerald, S. Hwang, and R. Dubrow, Growth and development and other risk factors for osteosarcoma in children and young adults, Int. J. Epidemiol, vol.26, issue.2, pp.272-278, 1997.

M. L. Broadhead, J. Clark, D. E. Myers, C. R. Dass, and P. Choong, The Molecular Pathogenesis of Osteosarcoma: A Review, Sarcoma, 2011.

A. Longhi, A. Pasini, A. Cicognani, F. Baronio, A. Pellacani et al., Height as a risk factor for osteosarcoma, J. Pediatr. Hematol. Oncol, vol.27, issue.6, pp.314-318, 2005.

M. Okasha, D. Gunnell, J. Holly, D. Smith, and G. , Childhood growth and adult cancer. Best Pract. Res. Clin. Endocrinol. Metab, vol.16, issue.2, pp.225-241, 2002.

S. Pekic, V. Popovic, . Management, and . Endocrine-disease, GH therapy and cancer risk in hypopituitarism: what we know from human studies, Eur. J. Endocrinol, vol.169, issue.5, pp.89-97, 2013.

J. Guevara-aguirre and A. L. Rosenbloom, Obesity, diabetes and cancer: insight into the relationship from a cohort with growth hormone receptor deficiency, Diabetologia, vol.58, issue.1, pp.37-42, 2015.

Y. Lin, S. Li, P. Cao, L. Cheng, M. Quan et al., The effects of recombinant human GH on promoting tumor growth depend on the expression of GH receptor in vivo, J. Endocrinol, vol.211, issue.3, pp.249-256, 2011.

A. B. Hill, The environment and disease: association or causation?, J. R. Soc. Med, vol.108, issue.1, pp.32-37, 1965.
DOI : 10.1177/0141076814562718
URL : http://europepmc.org/articles/pmc1898525?pdf=render

, Premiers résultats de l'étude épidémiologique sur la tolérance à long terme -Lettre aux professionnels de santé -ANSM : Agence nationale de sécurité du médicament et des produits de santé, 2016.

, European Medicines Agency -News and Events -European Medicines Agency to review the safety of somatropin-containing medicines, 2016.

C. Research, Drug Safety and Availability -FDA Drug Safety Communication: Safety review update of Recombinant Human Growth Hormone (somatropin) and possible increased risk of death, 2016.

R. G. Rosenfeld, P. Cohen, L. L. Robison, B. B. Bercu, P. Clayton et al., Long-term surveillance of growth hormone therapy, J. Clin. Endocrinol. Metab, vol.97, issue.1, pp.68-72, 2012.

R. G. Rosenfeld, Pharmacological interventions for short stature: pros and cons, Nestlé Nutr. Inst. Workshop Ser, vol.71, pp.207-217, 2013.
DOI : 10.1159/000342640

M. A. Sperling, Long-term therapy with growth hormone: bringing sagacity to SAGHE, J. Clin. Endocrinol. Metab, vol.97, issue.1, pp.81-83, 2012.

S. Malozowski, Reports of Increased Mortality and GH: Will This Affect Current Clinical Practice?, J. Clin. Endocrinol. Metab, vol.97, issue.2, pp.380-383, 2012.

N. T. Laventhal, M. Shuchman, and D. E. Sandberg, Warning about warnings: weighing risk and benefit when information is in a state of flux, Horm. Res. Paediatrics, vol.79, issue.1, pp.4-8, 2013.

, Études observationnelles en pharmaco-épidémiologie : retour... Available at, 2016.

B. L. Strom and . Pharmacoepidemiology, , 2006.

A. J. Swerdlow, R. Cooke, D. Beckers, B. Borgström, G. Butler et al., Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study, J. Clin. Endocrinol. Metab, vol.102, issue.5, pp.1661-1672, 2017.

M. Kundi, Causality and the interpretation of epidemiologic evidence, Environ. Health Perspect, vol.114, issue.7, pp.969-974, 2006.

J. Coste, Diverging approaches of pharmacovigilance and pharmacoepidemiology to assessing drug safety: epistemological and ethical implications, Pharmacoepidemiol. Drug Saf, 2017.

D. B. Allen, Growth hormone post-marketing surveillance: safety, sales, and the unfinished task ahead, J Clin Endocrinol Metab, vol.95, pp.52-55, 2010.

Y. Chhabra, M. J. Waters, and A. J. Brooks, Role of the growth hormone-IGF-1 axis in cancer, Expert Rev Endocrinol Metab, vol.6, pp.71-84, 2011.

P. J. Jenkins, A. Mukherjee, and S. M. Shalet, Does growth hormone cause cancer?, Clin Endocrinol, vol.64, pp.115-121, 2006.

J. C. Carel, E. Ecosse, and F. Landier, Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study, J Clin Endocrinol Metab, vol.97, pp.416-425, 2012.

D. Rizzoni, E. Porteri, and A. Giustina, Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries, Hypertension, vol.43, pp.561-565, 2004.

G. Brevetti, P. Marzullo, and A. Silvestro, Early vascular alterations in acromegaly, J Clin Endocrinol Metab, vol.87, pp.3174-3179, 2002.

R. Manara, P. Maffei, and V. Citton, Increased rate of intracranial saccular aneurysms in acromegaly: an MR angiography study and review of the literature, J Clin Endocrinol Metab, vol.96, pp.1292-1300, 2011.

P. Delafontaine, Y. H. Song, and Y. Li, Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels, Arterioscler Thromb Vasc Biol, vol.24, pp.435-444, 2004.

G. Li, D. Rincon, J. P. Jahn, and L. A. , Growth hormone exerts acute vascular effects independent of systemic or muscle insulin-like growth factor I, J Clin Endocrinol Metab, vol.93, pp.1379-1385, 2008.

C. L. Sudlow and C. P. Warlow, Comparable studies of the incidence of stroke and its pathological types results from an international collaboration, Stroke, vol.28, pp.491-499, 1997.

M. Lemesle, C. Milan, J. Faivre, T. Moreau, M. Giroud et al., Incidence trends of ischemic stroke and transient ischemic attacks in a well-defined French population from 1985 through 1994, Stroke, vol.30, pp.371-377, 1999.

P. Rothwell, A. J. Coull, and M. Giles, Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from, Oxford Vascular Study). Lancet, vol.363, pp.1925-1933, 1981.

E. B. Hook and R. R. Regal, Recommendations for presentation and evaluation of capture-recapture estimates in epidemiology, J Clin Epidemiol, vol.52, pp.917-926, 1999.

E. B. Hook and R. R. Regal, Capture-recapture methods in epidemiology: methods and limitations, Epidemiol Rev, vol.17, pp.243-264, 1995.

J. C. Carel, E. Ecosse, and M. Nicolino, Adult height after long term treatment with recombinant growth hormone for idiopathic isolated growth hormone deficiency: observational follow up study of the French population based registry, BMJ, vol.325, p.70, 2002.

L. J. Machlin, Effect of porcine growth hormone on growth and carcass composition of the pig, J Anim Sci, vol.35, pp.794-800, 1972.

J. Jakubowski and B. Kendall, Coincidental aneurysms with tumours of pituitary origin, J Neurol Neurosurg Psychiatry, vol.41, pp.972-979, 1978.

S. Wakai, T. Fukushima, T. Furihata, and K. Sano, Association of cerebral aneurysm with pituitary adenoma, Surg Neurol, vol.12, pp.503-507, 1979.

M. Acqui, L. Ferrante, B. Fraioli, F. Cosentino, A. Fortuna et al., Association between intracranial aneurysms and pituitary adenomas: aetiopathogenetic hypotheses, Neurochirurgia, vol.30, pp.177-181, 1987.

B. Weir, Pituitary tumors and aneurysms: case report and review of the literature, Neurosurgery, vol.30, pp.585-591, 1992.

Y. Shimizu, H. Imano, and T. Ohira, Adult height and body mass index in relation to risk of total stroke and its subtypes: the Circulatory Risk in Communities Study, J Stroke Cerebrovasc Dis, vol.23, pp.667-674, 2014.

, Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis, Int J Epidemiol, vol.41, pp.1419-1433, 2012.

K. Honjo, H. Iso, M. Inoue, and S. Tsugane, Adult height and the risk of cardiovascular disease among middle, pp.13-21

Y. M. Song, G. D. Smith, and J. Sung, Adult height and causespecific mortality: a large prospective study of South Korean men, Am J Epidemiol, vol.158, pp.479-485, 2003.

C. M. Lee, F. Barzi, and M. Woodward, Adult height and the risks of cardiovascular disease and major causes of death in the Asia-Pacific region: 21,000 deaths in 510,000 men and women, Int J Epidemiol, vol.38, pp.1060-1071, 2009.

S. Miskinyte, M. G. Butler, and D. Hervé, Loss of BRCC3 deubiquitinating enzyme leads to abnormal angiogenesis and is associated with syndromic moyamoya, Am J Hum Genet, vol.88, pp.718-728, 2011.

D. J. Barker, P. D. Gluckman, K. M. Godfrey, J. E. Harding, J. A. Owens et al., Fetal nutrition and cardiovascular disease in adult life, Lancet, vol.341, pp.938-941, 1993.

S. J. Olshansky and T. T. Perls, New developments in the illegal provision of growth hormone for "anti-aging" and bodybuilding, JAMA, vol.299, pp.2792-2794, 2008.

N. Møller and J. Jørgensen, Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects, Endocr Rev, vol.30, issue.2, pp.152-177, 2009.

A. Vijayakumar, R. Novosyadlyy, Y. Wu, S. Yakar, and D. Leroith, Biological effects of growth hormone on carbohydrate and lipid metabolism, Growth Horm IGF Res, vol.20, issue.1, pp.1-7, 2010.

M. A. Sperling, Traditional and novel aspects of the metabolic actions of growth hormone, Growth Horm IGF Res, vol.28, pp.69-75, 2015.

A. Colao, D. Ferone, P. Marzullo, and G. Lombardi, Systemic complications of acromegaly: epidemiology, pathogenesis, and management, Endocr Rev, vol.25, issue.1, pp.102-152, 2004.

S. Fieffe, I. Morange, P. Petrossians, P. Chanson, V. Rohmer et al., Delemer B; French Acromegaly Registry. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry, Eur J Endocrinol, vol.164, issue.6, pp.877-884, 2011.

, Critical Evaluation of the Safety of Recombinant Human Growth Hormone Administration. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society, J Clin Endocrinol Metab, vol.86, issue.5, pp.1868-1870, 2001.

J. Bell, K. L. Parker, R. D. Swinford, A. R. Hoffman, T. Maneatis et al., Long-term safety of recombinant human growth hormone in children, J Clin Endocrinol Metab, vol.95, issue.1, pp.167-177, 2010.

M. Van-dijk, E. Bannink, Y. K. Van-pareren, P. Mulder, and A. Hokken-koelega, Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (SGA) and untreated short SGA controls, J Clin Endocrinol Metab, vol.92, issue.1, pp.160-165, 2007.

K. Stochholm and G. Johannsson, Reviewing the safety of GH replacement therapy in adults, Growth Horm IGF Res, vol.25, issue.4, pp.149-157, 2015.

J. Carel, E. Ecosse, F. Landier, D. Meguellati-hakkas, F. Kaguelidou et al., Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study, J Clin Endocrinol Metab, vol.97, issue.2, pp.416-425, 2012.

A. Poidvin, E. Touzé, E. Ecosse, F. Landier, Y. Béjot et al., Growth hormone treatment for childhood short stature and risk of stroke in early adulthood, Neurology, vol.83, issue.9, pp.780-786, 2014.

M. F. Rolland-cachera, T. J. Cole, M. Sempé, J. Tichet, C. Rossignol et al., Body mass index variations: centiles from birth to 87 years, Eur J Clin Nutr, vol.45, issue.1, pp.13-21, 1991.

G. Moulis, M. Lapeyre-mestre, A. Palmaro, G. Pugnet, J. Montastruc et al., French health insurance databases: what interest for medical research, Rev Med Interne, vol.36, issue.6, pp.411-417, 2015.

P. Tuppin, L. De-roquefeuil, A. Weill, P. Ricordeau, M. et al., French national health insurance information system and the permanent beneficiaries sample, Rev Epidemiol Sante Publique, vol.58, issue.4, pp.286-290, 2010.

C. Giannini, A. Mohn, and F. Chiarelli, Growth abnormalities in children with type 1 diabetes, juvenile chronic arthritis, and asthma, Int. J. Endocrinol, p.265954, 2014.

W. Bonfig, T. Kapellen, A. Dost, M. Fritsch, T. Rohrer et al., jcem of the German Working Group for Pediatric Diabetology and the German Bundesministerium f ¨ ur Bildung und Forschung Competence Net for Diabetes Mellitus. Growth in children and adolescents with type 1 diabetes, J Pediatr, vol.160, issue.6, pp.900-903, 2012.

C. Lévy-marchal and P. Czernichow, Small for gestational age and the metabolic syndrome: which mechanism is suggested by epidemiological and clinical studies?, Horm Res, vol.65, issue.3, pp.123-130, 2006.

P. Saenger, P. Czernichow, I. Hughes, and E. O. Reiter, Small for gestational age: short stature and beyond, Endocr Rev, vol.28, issue.2, pp.219-251, 2007.

P. H. Whincup, S. J. Kaye, C. G. Owen, R. Huxley, D. G. Cook et al., Birth weight and risk of type 2 diabetes: a systematic review, JAMA, vol.300, issue.24, pp.2886-2897, 2008.

T. Harder, E. Rodekamp, K. Schellong, and J. W. Dudenhausen, Plagemann A. Birth weight and subsequent risk of type 2 diabetes: a meta-analysis, Am J Epidemiol, vol.165, issue.8, pp.849-857, 2007.

P. Ricci, . Blotì-ere-p-o, and A. Weill, Diabète traité: quellesévolutionsquelles´quellesévolutions entre, 2000.

C. L. Ronchi, V. Varca, P. Beck-peccoz, E. Orsi, F. Donadio et al., Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors, J Clin Endocrinol Metab, vol.91, issue.1, pp.121-128, 2006.

R. H. Willemsen, S. P. Willemsen, and A. Hokken-koelega, Longitudinal changes in insulin sensitivity and body composition of small-forgestational-age adolescents after cessation of growth hormone treatment, J Clin Endocrinol Metab, vol.93, issue.9, pp.3449-3454, 2008.

S. De-kort, R. H. Willemsen, D. Van-der-kaay, and A. Hokkenkoelega, The effect of growth hormone treatment on metabolic and cardiovascular risk factors is similar in preterm and term short, small for gestational age children, Clin Endocrinol (Oxf), vol.71, issue.1, pp.65-73, 2009.

L. Mandereau-bruno, P. Denis, A. Fagot-campagna, and S. Fosse-edorh, Prevalence of people pharmacologically treated for diabetes and territorial variations in France in 2012, BEH, pp.493-499, 2014.